首页 | 本学科首页   官方微博 | 高级检索  
检索        

HP1188-IgY对感染幽门螺杆菌BALB/c小鼠的治疗作用
引用本文:韩飞,杨致邦,李建英,周政,彭方毅,姜海蓉,杜红心.HP1188-IgY对感染幽门螺杆菌BALB/c小鼠的治疗作用[J].中国病理生理杂志,2015,31(1):148-153.
作者姓名:韩飞  杨致邦  李建英  周政  彭方毅  姜海蓉  杜红心
作者单位:1. 重庆三峡中心医院检验科, 重庆 404100;
2. 重庆医科大学基础医学院病原生物学教研室, 重庆 400016;
3. 重庆理工大学药学与生物工程学院制药工程专业, 重庆 400054;
4. 重庆市江津区中心医院科教部, 重庆 402260
基金项目:重庆市万州区科委重点科技计划
摘    要:目的:评价抗幽门螺杆菌(Helicobacter pylori,H.pylori)HP1188蛋黄抗体(HP1188-immunoglobulin yolk,HP1188-Ig Y)对BALB/c小鼠胃内H.pylori感染的治疗效果。方法:建立H.pylori感染BALB/c小鼠的动物模型,将建模成功的80只小鼠随机分为8组,每组10只。第1组(抗生素治疗组)、第2组(1 mg HP1188-Ig Y)、第3组(1 mg HP1188-Ig Y+30%硫糖铝)、第4组(5 mg HP1188-Ig Y)、第5组(5 mg HP1188-Ig Y+30%硫糖铝)、第6组(PBS对照组)和第7组(30%硫糖铝对照组)分别连续治疗10 d,每天1次;第8组间隔48 h皮下注射2.5 mg HP1188-Ig Y,共2次;另10只正常小鼠为第9组(健康对照组)。处理完成2周后取各组小鼠胃组织作H.pylori培养、快速尿素酶试验、PCR检测H.pylori特异性vac A和cag A及病理组织学检查,观察H.pylori清除情况并进行评分。结果:在小鼠体内,灌胃(1 mg HP1188-Ig Y+30%硫糖铝)即可有效治疗H.pylori感染引起的胃黏膜损害,其治疗效果与抗生素相似。结论:成功构建了H.pylori感染的BALB/c小鼠模型,选择30%硫糖铝为抗体保护剂,经口服HP1188-Ig Y可抑制小鼠胃内H.pylori感染。

关 键 词:幽门螺杆菌  HP1188蛋黄抗体  硫糖铝  
收稿时间:2014-05-21

Treatment of Helicobacter pylori-infected gastritis in BALB/c mice by HP1188-IgY
HAN Fei,YANG Zhi-bang,LI Jian-ying,ZHOU Zheng,PENG Fang-yi,JIANG Hai-rong,DU Hong-xin.Treatment of Helicobacter pylori-infected gastritis in BALB/c mice by HP1188-IgY[J].Chinese Journal of Pathophysiology,2015,31(1):148-153.
Authors:HAN Fei  YANG Zhi-bang  LI Jian-ying  ZHOU Zheng  PENG Fang-yi  JIANG Hai-rong  DU Hong-xin
Institution:1. Department of Medical Laboratory, Chongqing Three Gorges Central Hospital, Chongqing 404100, China;
2. Department of Pathogen Biology, School of Basic Medicine, Chongqing Medical University, Chongqing 400016, China;
3. Pharmaceutical Engineering Specialty, School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing 400054, China;
4. Department of Science and Education, Jiangjin Central Hospital, Chongqing 402260, China
Abstract:AIM: To evaluate the effects of treatment with HP1188-immunoglobulin yolk (HP1188-IgY) on Helicobacter pylori (H. pylori)-infected gastritis in BALB/c mice. METHODS: BALB/c mice were used to establish an animal model of H.pylori-infected gastritis, and the mice were divided into 8 groups (10 mice per group). Oral antibiotics were used in group 1, 1 mg HP1188-IgY in group 2, 1 mg HP1188-IgY plus 30% sucralfate in group 3, 5 mg HP1188-IgY in group 4, 5 mg HP1188-IgY plus 30% sucralfate in group 5, PBS in group 6, and 30% sucralfate in group 7 with the treatment once per day for 10 d; and 2.5 mg HP1188-IgY was injected hypodermically twice with a 48-h interval in group 8. Another 10 mice were used as normal control in group 9. The planting of bacteria in the stomach was assayed by bacterial culture, rapid urease test, PCR and pathological sectioning. RESULTS: Intragastric administration with 1 mg HP1188-IgY plus 30% sucralfate per day effectively cured the injury of gastric mucosa caused by H.pylori infection, and the effect has no significant difference compared with antibiotics (P>0.05). CONCLUSION: We establish a BALB/c mouse model infected with H.pylori successfully. Sucralfate (30%) is an ideal protectant for HP1188-IgY, which might decrease H.pylori infection in the stomach of BALB/c mice by oral inoculation.
Keywords:KEY WORDS] Helicobacter pylori  HP1188-immunoglobulin yolk  Sucralfate
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《中国病理生理杂志》浏览原始摘要信息
点击此处可从《中国病理生理杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号